Evidence map›Paper›PMID 28223550›Full record

ArticleOncotarget2017

NADH autofluorescence, a new metabolic biomarker for cancer stem cells: Identification of Vitamin C and CAPE as natural products targeting "stemness".

Gloria Bonuccelli, Ernestina Marianna De Francesco, Rianne de Boer, Herbert B Tanowitz, Michael P Lisanti

Registry-linked trialOpen access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03070262 (Caffeic Acid for Advanced Esophageal Squamous Cell Cancer), which is not on this map. Cited by 45 papers.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed
5.0field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03070262 phase3unknown statusnot on this map

Caffeic Acid for Advanced Esophageal Squamous Cell Cancer: A Randomized, Double-blind, and Multicenter Trial in Chinese Patients

TypeinterventionalSponsorThe First Affiliated Hospital of Henan University of Science and TechnologyRan2017 to 2021Enrolled300ConditionsEsophagus CancerArmsCA, placebo group
3 · Its place in the literature

Who cites it

45 citing papers in PubMed, 74 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 3 countries.

Gloria BonuccelliThe Paterson Building, University of Manchester, Withington, M20 4BX, United Kingdom.
Ernestina Marianna De FrancescoThe Paterson Building, University of Manchester, Withington, M20 4BX, United Kingdom.
Rianne de BoerThe Paterson Building, University of Manchester, Withington, M20 4BX, United Kingdom.
Herbert B TanowitzDepartments of Pathology and Medicine, Albert Einstein College of Medicine, Bronx, NY, 10461, USA.
Michael P LisantiTranslational Medicine, School of Environment and Life Sciences, Biomedical Research Centre, University of Salford, Greater Manchester, M5 4WT, United Kingdom.
University of Manchester · GBAlbert Einstein College of Medicine · USUniversity of Calabria · ITUniversity of Salford · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Here, we assembled a broad molecular "tool-kit" to interrogate the role of metabolic heterogeneity in the propagation of cancer stem-like cells (CSCs). First, we subjected MCF7 cells to "metabolic fractionation" by flow cytometry, using fluorescent mitochondrial probes to detect PCG1α activity, as well ROS and hydrogen-peroxide (H2O2) production; NADH levels were also monitored by auto-fluorescence. Then, the various cell populations were functionally assessed for "stem cell activity", using the mammosphere assay (3D-spheroids). Our results indicate that a sub-population of MCF7 cells, with increased PGC1α activity, high mitochondrial ROS/H2O2 production and high NADH levels, all form mammospheres with a higher efficiency. Thus, it appears that mitochondrial oxidative stress and the anti-oxidant response both contribute to the promotion of mitochondrial biogenesis and oxidative metabolism in CSCs. Further validation was provided by using specific inhibitors to target metabolic processes (the NAD+ salvage pathway, glycolysis, mitochondrial protein synthesis and OXPHOS), significantly reducing CSC propagation. As a consequence, we have now identified a variety of clinically-approved drugs (stiripentol), natural products (caffeic acid phenyl ester (CAPE), ascorbic acid, silibinin) and experimental pharmaceuticals (actinonin, FK866, 2-DG), that can be used to effectively inhibit CSC activity. We discuss the use of CAPE (derived from honey-bee propolis) and Vitamin C, as potential natural therapeutic modalities. In this context, Vitamin C was ~10 times more potent than 2-DG for the targeting of CSCs. Similarly, stiripentol was between 50 to 100 times more potent than 2-DG.

Indexed as

Antineoplastic AgentsAscorbic AcidBiomarkers, TumorCaffeic AcidsCell ProliferationDioxolanesFlow CytometryHumansMCF-7 CellsNADNeoplastic Stem CellsOptical ImagingPhenylethyl AlcoholAntineoplastic AgentsAscorbic AcidBiomarkers, Tumorcaffeic acid phenethyl esterCaffeic AcidsDioxolanesNADPhenylethyl Alcoholstiripentolcancer stem-like cellsmetabolic cell fractionationmetabolic heterogeneitymitochondriaNADH

Identifiers

PMID28223550
PMCPMC5400535
OpenAlexW2591365492

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.